Top

Published in:

01-03-2013 | Original Article

Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort

Authors: J. Sanfélix-Genovés, G. Sanfélix-Gimeno, S. Peiró, I. Hurtado, C. Fluixà, A. Fuertes, J. C. Campos, V. Giner, C. Baixauli

Published in: Osteoporosis International | Issue 3/2013

Abstract

Summary

This study provides information on the prevalence of the most important risk factors for osteoporosis and osteoporotic fracture in a large sample of women and men from the Valencia region and also provides the FRAX 10-year major and hip fracture risks for this population, as well as data about the use of diagnostic tests and antiosteoporotic treatments.

Introduction

The purpose of this study was to describe demographic characteristics, osteoporosis risk factors, the 10-year risk of osteoporotic fracture, and the use of densitometry and antiosteoporotic treatments in the Valencia region, Spain.

Methods

A cross-sectional study using the ESOSVAL cohort baseline data was conducted. We analyze the data from 5,310 women and 5,725 men aged 50 and over who attended to 272 collaborating primary care centers in 2009–2010. We collected the demographic, anthropometric, clinical, and pharmacy data from the electronic medical record.

Results

The mean age of participants was 64.3 years old for women and 65.6 years old for men. The most frequent fracture risk factors were sedentary life (22.2 %) and previous fracture (15.8 %) in women and low calcium intake (21.4 %) and current smoker (20.9 %) in men. According to FRAX^®, the 10-year risk of presenting a major fracture was 5.5 % for the women and 2.8 % for the men. The 10-year risk for hip fracture was 1.9 and 1.1 % for the women and the men, respectively; 23.8 % of the women and 5.2 % of the men had a densitometry test, 27.7 % of the women and 3.5 % of the men were taking calcium and/or vitamin D supplements, and 28.2 % of the women (22.0 % in the 50–64 age group) and 2.3 % of the men were taking antiosteoporotic drugs.

Conclusions

The prevalence of certain fracture risk factors not included in the FRAX tool (sedentary life, falls, low calcium intake) is high. In young women, their low risks estimated by FRAX contrast with the high figures for densitometry testing and treatment.

Available only for authorised users

Sanfélix-Genovés J, Reig-Molla B, Sanfélix-Gimeno G, Peiró S, Graells-Ferrer M, Vega-Martínez M et al (2010) The population-based prevalence of osteoporotic vertebral fracture and densitometric osteoporosis in postmenopausal women over 50 in Valencia, Spain (the FRAVO study). Bone 47(3):610–616PubMedCrossRef

Sanfélix-Genovés J, Hurtado I, Sanfélix-Gimeno G, Reig-Molla B, Peiró S (2011) Impact of osteoporosis and vertebral fractures on quality-of-life. A population-based study in Valencia, Spain (the FRAVO study). Health Qual Life Outcomes 6:9–20

Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14(5):383–388PubMedCrossRef

Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4(6):368–381PubMedCrossRef

Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK (2008) Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149(6):404–415PubMed

National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. [Available at: http://www.nof.org/]

Management of osteoporosis in postmenopausal women (2010) Position statement of (2010) The North American Menopause Society. Menopause 17(1):25–54CrossRef

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF et al (2010) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(Suppl 3):1–37PubMed

Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254–1259PubMedCrossRef

10.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285(6):785–795CrossRef

11.

Kanis JA, on behalf of the World Health Organisation Scientific Group (2007) Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. [Available at http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf]. Accessed 15 January 2011.

12.

Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:b4229. doi:10.1136/bmj.b4229 PubMedCrossRef

13.

van den Bergh JP, van Geel TA, Lems WF, Geusens PP (2010) Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep 8(3):131–137PubMedCrossRef

14.

Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD et al (2007) Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA 298(20):2389–2398PubMedCrossRef

15.

Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA et al (2011) FRAX(®) position development conference members. J Clin Densitom 14(3):171–180PubMedCrossRef

16.

Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046PubMedCrossRef

17.

González-Macías J, Marín F, Vila J, Díez-Pérez A, Abizanda M, Alvarez R et al (2004) Risk factors for osteoporosis and osteoporotic fractures in a series of 5,195 women older than 65 years. Med Clin (Barc) 123(3):85–89CrossRef

18.

Vila J, Marín F, González-Macías J, Martín D, Tojeiro S, Díez-Pérez A, representación de los investigadores del proyecto ECOSAP (2009) Validation of an algorithm to calculate the absolute risk of non-vertebral fragility fractures in a cohort of postmenopausal women. Med Clin (Barc) 133(13):501–505CrossRef

19.

Sanfélix-Genovés J, Peiró S, Sanfélix-Gimeno G, Giner V, Gil V, Pascual M et al (2010) Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study. BMC Publ Health 10:153CrossRef

20.

Azagra R, Roca G, Encabo G, Prieto D, Aguyé A, Zwart M et al (2011) Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain. BMC Musculoskelet Disord 12:30PubMedCrossRef

21.

Tebé C, Espallargues M, Estrada MD, Kotzeva A, del Río LM, Di Gregorio S (2011) Validación del modelo predictivo de fractura osteoporótica FRAX. Ministerio de Ciencia e Innovación. Agència d’Informació, Avaluació i Qualitat en Salut, Madrid

22.

González-Macías J, Marin F, Vila J, Díez-Pérez A (2012) Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort. Bone 50(1):373–377PubMedCrossRef

23.

Sanfélix-Genovés J, Peiró S, Sanfélix-Gimeno G, Hurtado I, Pascual de la Torre M, Trillo-Mata JL et al (2010) Impact of a multifaceted intervention to improve the clinical management of osteoporosis. The ESOSVAL-F study. BMC Health Serv Res 10:292PubMedCrossRef

24.

Sanfélix-Gimeno G, Sanfélix-Genovés J, Peiró S, Hurtado I, Trillo JL, Usó R et al (2011) Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia region (Spain). The ESOSVAL-AD study. BMC Musculoskelet Disord 12:178PubMedCrossRef

25.

Spanish Health Survey. Encuesta Nacional de Salud 2009. Available at http://www.ine.es/metodologia/t15/t1530419cues06.htm. Accessed 15 January 2012

26.

Carretero Baeza ML, Gómez Vazquez M, coord (1995) Tablas de Composición de Alimentos Españoles. Madrid: Ministerio de Sanidad y Consumo

27.

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385–397PubMedCrossRef

28.

Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864–1873PubMed

29.

Anuari Estadístic Comunitat Valenciana (2006) Valencia: Institut Valencià d’Estadística; 2007

30.

Arana-Arri E, Gutiérrez-Ibarluzea I, Ecenarro Mugaguren A, Asua Batarrita J (2007) Prevalence of certain osteoporosis-determining habits among post menopausal women in the Basque Country, Spain, in 2003. Rev Esp Salud Publica 81(6):647–656PubMedCrossRef

31.

Luz Rentero M, Carbonell C, Casillas M, González Béjar M, Berenguer R (2008) Risk factors for osteoporosis and fractures in postmenopausal women between 50 and 65 years of age in a primary care setting in Spain: a questionnaire. Open Rheumatol J 2:58–63PubMedCrossRef

32.

Roig Vilaseca D, Gómez Vaquero C, Hoces Otero C, Nolla JM (2010) Fracture risk calculated with the FRAX index in patients with osteoporosis treated and untreated. Med Clin (Barc) 134(5):189–193CrossRef

33.

Azagra Ledesma R, Prieto-Alhambra D, Encabo Duró G, Casado Burgos E, Aguyé Batista A, Díez-Pérez A, grupo de estudio FRIDEX (2011) Usefulness of FRAX tool for the management of osteoporosis in the Spanish female population. Med Clin (Barc) 136(14):613–619CrossRef

34.

Del Río BL, Tebé Cordomi C, Johansson H, Di Gregorio MS, Estrada Sabadell D, Espallargues Carreras M (2011) Evaluación del riesgo absoluto de fractura mediante herramienta FRAX® en una cohorte española. Rev Osteoporos Metab Miner 3(2):85–93

35.

Tebé C, del Río LM, Casas L, Estrada MD, Kotzeva A, Di Gregorio S, Espallargues M (2011) Risk factors for fragility fractures in a cohort of Spanish women. Gac Sanit 25(6):507–512PubMedCrossRef

36.

de Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T (2010) Clinical characteristics of patients under treatment for osteoporosis in a primary care centre. Who do we treat? Aten Primaria 42(11):559–563PubMedCrossRef

37.

Albrand G, Munoz F, Sornay-Rendu E, DuBoeuf F, Delmas PD (2003) Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32(1):78–85PubMedCrossRef

38.

Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O (2001) An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12(7):519–528PubMedCrossRef

39.

McGrother CW, Donaldson MM, Clayton D, Abrams KR, Clarke M (2002) Evaluation of a hip fracture risk score for assessing elderly women: the Melton osteoporotic fracture (MOF) study. Osteoporos Int 13(1):89–96PubMedCrossRef

40.

Warensjö E, Byberg L, Melhus H, Gedeborg R, Mallmin H, Wolk A et al (2011) Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 342:d1473PubMedCrossRef

41.

Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA et al (2011) Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 22(3):817–827PubMedCrossRef

42.

Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis J et al (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25(11):2350–2358PubMedCrossRef

43.

Couris CM, Chapurlat RD, Kanis JA, Johansson H, Burlet N, Delmas PD et al (2011) FRAX(®) probabilities and risk of major osteoporotic fracture in France. Osteoporos Int. doi:10.1007/s00198-011-1883-8

44.

Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC et al (2010) Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 25(7):1506–1511PubMedCrossRef

45.

Trémollieres F, Cochet T, Cohade C, Pouillès JM, Ribot C (2010) Fracture risk in early postmenopausal women assessed using FRAX. Joint Bone Spine 77(4):345–348PubMedCrossRef

Title: Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort
Authors: J. Sanfélix-Genovés
G. Sanfélix-Gimeno
S. Peiró
I. Hurtado
C. Fluixà
A. Fuertes
J. C. Campos
V. Giner
C. Baixauli
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 3/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-2018-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2013

Undercarboxylated osteocalcin is positively associated with free testosterone in male patients with type 2 diabetes mellitus

Recurrent bilateral metatarsal “stress-and-insufficiency” fractures in a levodopa-treated young woman with Parkinson's disease

Updated fracture incidence rates for the Italian version of FRAX®

Prevention of falls in the elderly—a review

Differential features of muscle fiber atrophy in osteoporosis and osteoarthritis

Cost and management of males with closed fractures